Please use this identifier to cite or link to this item:
http://repo.knmu.edu.ua/handle/123456789/27475Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Koteliukh, Mariia | - |
| dc.contributor.author | Котелюх, Марія Юріївна | - |
| dc.date.accessioned | 2020-11-23T19:17:38Z | - |
| dc.date.available | 2020-11-23T19:17:38Z | - |
| dc.date.issued | 2020-10 | - |
| dc.identifier.citation | Koteliukh M. The role of irisin, adropin, ctrp-3 in the development adverse cardiac events following an acute myocardial infarction in patients with obesity / M. Koteliukh // ISIC-2020 : [International Scientific Interdisciplinary Conference for medical students and young scientists, Kharkiv, 8–9 October, 2018] : abstract book / KNMU. – Kharkiv, 2020. – P. 76. | en_US |
| dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/27475 | - |
| dc.description.abstract | Irisin has been shown to have protective effects against lung and heart damage. However, whether irisin affects acute myocardial infarction (AMI) with concomitant obesity remains unclear. Adropin is a peptide hormone that is involved in maintaining insulin sensitivity and is a new regulator of endothelial cells. CTRP3 is regulatory protein which can effected on the development of adverse cardiac events following an AMI with concomitant obesity. | en_US |
| dc.language.iso | en | en_US |
| dc.subject | miocardial infarction | en_US |
| dc.subject | obesity | en_US |
| dc.title | The role of irisin, adropin, ctrp-3 in the development adverse cardiac events following an acute myocardial infarction in patients with obesity | en_US |
| dc.type | Thesis | en_US |
| Appears in Collections: | Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 2 і клінічної імунології та алергології ім. ак. Л.Т. Малої | |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.